Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of PD-1 inhibitor + lenvatinib + low-dose bevacizumab interventional therapy for unresectable hepatocellular carcinoma
ChiCTR2600135308Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective response rate and Duration of response. Started Sep 2022; status: completed.
02
Drugs
lenvatinibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600135308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135308.